This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 32.0 kDa. The protein migrates as 34-44 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-HPLC.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human BCMA, Fc Tag (HPLC verified) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human BCMA, Fc Tag (Cat. No. BC7-H5254) was greater than 90% as determined by SEC-HPLC.
Immobilized Biotinylated Human BAFF, His,Avitag (Cat. No. BAF-H82Q2) at 1 μg/mL (100 μL/well) on streptavidin precoated (0.2 μg/well) plate, can bind Human BCMA, Fc Tag (Cat. No. BC7-H5254) with a linear range of 0.1-0.8 ng/mL (QC tested).
Immobilized Human BCMA, Fc Tag (Cat. No. BC7-H5254) at 2 μg/mL (100 μL/well) can bind Anti-Human BCMA Mab with a linear range of 0.1-1.6 ng/mL (Routinely tested).
Loaded Human APRIL, His,Flag Tag, active trimer (Cat. No. APL-H52D1) on HIS1K Biosensor, can bind Human BCMA, Fc Tag (Cat. No. BC7-H5254) with an affinity constant of 1.88 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
293 cells were transfected with anti-BCMA-scFv and RFP tag. 2e5 of the cells were first stained with B. human BCMA / TNFRSF17 protein, Fc tag (Cat. No. BC7-H5254, 3 μg/ml) and C. human Fc tag protein control, followed by FITC-conjugated anti-human IgG Fc antibody. A. Non-transfected 293 cells and C. human Fc tag protein control were used as negative control. RFP was used to evaluate CAR (anti-BCMA-scFv) expression and FITC was used to evaluate the binding activity of human BCMA / TNFRSF17 protein, Fc tag (Cat. No. BC7-H5254).
Authors: Berahovich R, et al
Journal: Cancers (Basel) 2019
Application: Flow Cytometry
Authors: Berahovich R, et al.
Journal: Cancers (Basel) 2018
Application: Flow Cytometry
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.